Qlife carries out a SEK 4,6m directed issue of convertibles
The board of directors of Qlife Holding AB (“Qlife” or the “Company”) has, pursuant to the authorization granted by the annual general meeting on 4 May 2023, resolved on a directed issue of a convertible loan raising gross proceeds of SEK 4,647,035 prior to deduction of transaction costs. The convertible loan is expected to satisfy the Company’s financing need until the end of 2023.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
Term and Conversion price: The convertible has a 12-month term to maturity on 31 July 2024. The lenders, a consortium of microcap-investors, including Jinderman & Partners AB and Pensys AB, have the right to request conversion of the convertibles (amount owed, increased with set-up fee, ref. below) at a conversion price of SEK 0.08 per share, corresponding to the quota value of the Company’s shares. Conversion can be requested as from the date of registration of the convertibles with the Swedish Companies Registration Office to and including 30 July 2024.
Other terms: In connection with the disbursement of the convertible loan to the Company, a set-up fee of 66.67 per cent is added to the loan amount resulting in a total amount owed before interest of SEK 7,745, 058. The interest rate is two (2) per cent per month calculated on the loan amount increased with the set-up fee. The interest is calculated and paid in cash upon a potential conversion, and if not converted, then upon the maturity date. Interest only applies for the outstanding convertibles.
Deviation from the shareholders’ preferential rights etc.: The purpose of the convertible loan and the reason for the deviation from the shareholders’ preferential rights is the urgent need for ongoing working capital until the end of 2023 and thereby to improve the prospect for reaching the major milestones such as a strategic partnership. After careful consideration, the Board of Directors has taken into account the complexity of the convertibles, as well as the urgent nature of the Company’s funding need, which means that a rights issue is not considered suitable at this time. The Board of Directors’ assessment is hence that an issue with deviation from the shareholder's preferential rights is in the Company's and all shareholder's interest and therefore also justifies deviation from the main rule that issues of securities shall be carried out with preferential rights for the shareholders. The conversion price as well as the other terms for the convertible loan has been established through a negotiation at arm's length between the Company and the investors. In connection herewith, the Board of Directors has taken into account general market conditions that make it difficult to raise capital, whereby the terms and conditions for the convertible loans in an overall assessment are deemed to be in accordance with market conditions.
Share capital, shares, and dilution: Provided that all convertibles are converted into shares, the number of shares in Qlife will increase by 96,813,231, from 645,435,499 to 742,248,730. The share capital of the Company will increase by SEK 7.745.058.48, from SEK 51,634,839.92 to SEK 59,379,898.40. Thus, the convertible entails a potential maximum dilution of approximately 13 per cent based on the total number of shares in Qlife after conversion of the convertibles.
CEO, Thomas Warthoe comments: “We are happy to announce that we have managed to secure funding that is designed to cover Qlife’s short term financing needs till the end of 2023. Among other things, this allows us to intensify our dialogues with strategic partners, existing as well as new, in order to identify and pursue the fastest possible track to profitability. After all, we have invested +200mSEK in our patented technology and products to date. We know that there is a large and unmet demand for next generation easily available blood test technology at all levels, ranging from users/patients, to medical partners looking to take hospital-at-home concepts to the next level and large players in the pharma and medical device industries”.
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out below, on 2023-08-03 14:24 CET.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.
Important information
Publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from anyone else.
This press release is not a prospectus for the purposes of Regulation (EG) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Convertible Loan. In any EEA Member State, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of the Prospectus Regulation.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.
This press release does not constitute a recommendation concerning any investor’s decision regarding the Convertible Loan. Each investor or potential investor should conduct his, her or its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results.
Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, assessments, or current expectations about and targets for the Company’s future results of operations, financial condition, development, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by the fact that they contain words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Even if the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements, which are a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as of its date and are subject to change without notice. Neither the Company nor anyone else does undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.